Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol

Autor: J. C. Janssen, B. van Dijk, K. de Joode, M. J. B. Aarts, F. W. P. J. van den Berkmortel, C. U. Blank, M. J. Boers-Sonderen, A. J. M. van den Eertwegh, J. W. B. de Groot, M. Jalving, M. J. A. de Jonge, A. Joosse, E. Kapiteijn, A. M. Kamphuis-Huismans, K. A. T. Naipal, D. Piersma, B. Rikhof, H. M. Westgeest, G. Vreugdenhil, E. Oomen-de Hoop, E. E. A. P. Mulder, Astrid A. M. van der Veldt

Publikováno v: BMC Cancer, Vol 24, Iss 1, Pp 1-7 (2024)

Abstract Background Patients with irresectable stage III or metastatic melanoma presenting with poor prognostic factors are usually treated with a combination of immune checkpoint inhibitors (ICIs), consisting of ipilimumab and nivolumab. This combin

Externí odkaz: https://doaj.org/article/ca4c9e5c51fc40759d196932967e286e

Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ('ugly') locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT)

Autor: K. van den Berg, D. P. Schaap, E. L. K. Voogt, T. E. Buffart, H. M. W. Verheul, J. W. B. de Groot, C. Verhoef, J. Melenhorst, J. M. L. Roodhart, J. H. W. de Wilt, H. L. van Westreenen, A. G. J. Aalbers, M. van ‘t Veer, C. A. M. Marijnen, J. Vincent, L. H. J. Simkens, N. A. J. B. Peters, M. Berbée, I. M. Werter, P. Snaebjornsson, H. M. U. Peulen, I. G. van Lijnschoten, M. J. Roef, G. A. P. Nieuwenhuijzen, J. G. Bloemen, J. M. W. E. Willems, G. J. M. Creemers, J. Nederend, H. J. T. Rutten, J. W. A. Burger

Publikováno v: BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)

Abstract Background The presence of mesorectal fascia (MRF) invasion, grade 4 extramural venous invasion (EMVI), tumour deposits (TD) or extensive or bilateral extramesorectal (lateral) lymph nodes (LLN) on MRI has been suggested to identify patients

Externí odkaz: https://doaj.org/article/f7aba25b45ad4d6685361c2d2a075b23

Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial

Autor: E. E. A. P. Mulder, K. de Joode, S. Litière, A. J. ten Tije, K. P. M. Suijkerbuijk, M. J. Boers-Sonderen, G. A. P. Hospers, J. W. B. de Groot, A. J. M. van den Eertwegh, M. J. B. Aarts, D. Piersma, R. S. van Rijn, E. Kapiteijn, G. Vreugdenhil, F. W. P. J. van den Berkmortel, E. Oomen-de Hoop, M. G. Franken, B. Ryll, P. Rutkowski, S. Sleijfer, J. B. A. G. Haanen, A. A. M. van der Veldt

Publikováno v: BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)

Abstract Background The introduction of programmed cell death protein 1 (PD-1) blockers (i.e. nivolumab and pembrolizumab) has significantly improved the prognosis of patients with advanced melanoma. However, the long treatment duration (i.e. two yea

Externí odkaz: https://doaj.org/article/1258e8cfb799432884b62bfb054d74e9

Transanal total mesorectal excision and low anterior resection syndrome

Autor: Mathijs P. Hendriks, J M van Dodewaard-de Jong, J W T Dekker, J.A.G. van der Heijden, Bastiaan R. Klarenbeek, A J G Maaskant-Braat, D J A Sonneveld, T van Voorthuizen, Hein B.A.C. Stockmann, L B J Valkenburg-van Iersel, I.H.J.T. de Hingh, F W H Kloppenberg, G R Vink, Seyed M. Qaderi, F H Beverdam, K Talsma, A H W Schiphorst, J F J Vogelaar, Frans L. G. Erdkamp, H W M U van Grevenstein, W J Vles, Marco B. Polee, Jan B.M.J. Jansen, H H Helgason, P P L O Coene, Geerard L. Beets, E J Th Belt, A U G van Lent, Jan N. M. IJzermans, D D E Zimmerman, M L R Tjin-A-Ton, A J ten Tije, M Berbée, Leonie J. M. Mekenkamp, M P S Sie, Annebeth W. Haringhuizen, Koen C.M.J. Peeters, Maartje Los, A M T van der Velden, N A J B Peters, J W B de Groot, Martijn R. Meijerink, A Schouten van der Velden, A I de Vos, J.H.W. de Wilt, Lieke H.J. Simkens, E G G Verdaasdonk, José A. E. Custers, Peter Nieboer, Rob H.A. Verhoeven, M Vermaas, F Terheggen, P Quarles van Ufford-Mannesse, R Blankenburgh, R Hoekstra, R W M Schrauwen, Dirkje W. Sommeijer, R C Rietbroek, H van Cruijsen, L E A Spierings

Publikováno v: British journal of surgery, 108(8), 991-997. John Wiley and Sons Ltd
British Journal of Surgery, 108(8), 991-997. Wiley
PLCRC group 2021, ' Transanal total mesorectal excision and low anterior resection syndrome ', British Journal of Surgery, vol. 108, no. 8, pp. 991-997 . https://doi.org/10.1093/bjs/znab056
British Journal of Surgery, 108, 8, pp. 991-997
British Journal of Surgery, 108, 991-997
British Journal of Surgery, 108(8), 991-997. John Wiley and Sons Ltd

Background Bowel dysfunction after rectal cancer surgery is common, with some experiencing low anterior resection syndrome (LARS) is common after rectal cancer surgery. This study examined if transanal total mesorectal excision (TaTME) has a similar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c1fcf9a92def7659b2c98d0089aa720
http://www.scopus.com/inward/record.url?scp=85116172373&partnerID=8YFLogxK

Additional file 1 of Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled trial

Autor: M. S. Walma, S. J. Rombouts, L. J. H. Brada, I. H. Borel Rinkes, K. Bosscha, R. C. Bruijnen, O. R. Busch, G. J. Creemers, F. Daams, R. M. Van Dam, O. M. Van Delden, S. Festen, P. Ghorbani, D. J. De Groot, J. W. B. De Groot, N. Haj Mohammad, R. Van Hillegersberg, I. H. De Hingh, M. D’Hondt, E. D. Kerver, M. S. Van Leeuwen, M. S. Liem, K. P. Van Lienden, M. Los, V. E. De Meijer, M. R. Meijerink, L. J. Mekenkamp, C. Y. Nio, I. Oulad Abdennabi, E. Pando, G. A. Patijn, M. B. Polée, J. F. Pruijt, G. Roeyen, J. A. Ropela, M. W. J. Stommel, J. De Vos-Geelen, J. J. De Vries, E. M. Van Der Waal, F. J. Wessels, J. W. Wilmink, H. C. Van Santvoort, M. G. Besselink, I. Q. Molenaar

Additional file 1. Eligibility criteria RFA.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75e8d349b4d43d2067cda577d2e4fa95